Market Research Reports

  BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled   Molecular Oncology Diagnostics Market   -   A Global and Regional Analysis .  According to this study, the market for global molecular oncology diagnostics was valued at  $3.62 billion  in 2021 and is projected to reach  $12.13 billion  by 2032. The following factors are responsible for the increase in demand for molecular oncology diagnostics: Rising incidence of cancer cases Launch of innovative products in the molecular oncology diagnostics ecosystem Growth in biomarker identification and transformations in molecular techniques The detailed study is a compilation of 3 market data tables and 206 figures spread through 264 pages. Check out the detailed table of content here https://bisresearch.com/requestsample?id=1402type=toc Analyst's Take on the Market Projection According to  Nitish Kumar ,   Principal...

  In-silico drug discovery methods can help in identifying drug targets via bioinformatics tools. In addition, the methods can also be used to analyze the target structures for possible binding active sites. The use of computational methods and computers permeates all aspects of drug discovery and drug design. The methods are facilitating the access of massive amounts of data generated and transforming the extensive complex biological data into useful knowledge for the drug discovery process. These computational tools offer the advantage of delivering new drug candidates more quickly and at a lower cost. BIS Research's healthcare experts have found the  In-silico drug discovery market  to be one of the stable markets, and the global market is predicted to grow from $2,129.8 million in 2020 to $6,515.3 million in 2031 and is expected to grow with a CAGR of 10.52% during the forecast period 2021-2031. Factors fueling the growth of the market include the rising emphasis on r...

  Looking at the recent oncology care trends, the World Heart Foundation estimates the global cancer treatment expenditure to reach $XX billion in the year 2031.   The increase in overall burden provides an opportunity for several companies to step in and introduce their innovative products in the market. The emergence of the neoantigen cancer vaccine can be considered as an evident example of emerging oncology care that can possibly prevail over the existing hurdles of treatment un-specificity and safety benchmarks. The global neoantigen cancer vaccine industry analysis by BIS Research projects the market to grow at a significant CAGR of 77.73% during the forecast period 2024-2031. The  neoantigen cancer vaccine market  is expected to generate $35.5 million in revenue in 2024, owing to the expected launch of the first neoantigen vaccine, DC vaccine in the market. The neoantigen cancer vaccine market growth has been primarily attributed to major drivers in this marke...